BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20840788)

  • 1. Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy.
    Yoon SM; Shin KH; Kim JY; Seo SS; Park SY; Moon SH; Cho KH
    Radiat Oncol; 2010 Sep; 5():78. PubMed ID: 20840788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis.
    Choi KH; Lee SW; Yu M; Jeong S; Lee JW; Lee JH
    J Gynecol Oncol; 2019 Jan; 30(1):e1. PubMed ID: 30479085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can serial evaluation of serum SCC-Ag-level predict tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix treated with definitive chemoradiotherapy? A multi-institutional analysis.
    Choi KH; Yu M; Jeong S; Lee JH
    Int J Clin Oncol; 2020 Jul; 25(7):1405-1411. PubMed ID: 32221801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical values of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with cervical cancer treated with concurrent chemoradiotherapy.
    Yoon SM; Shin KH; Kim JY; Seo SS; Park SY; Kang S; Cho KH
    Int J Gynecol Cancer; 2007; 17(4):872-8. PubMed ID: 17343571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
    Reesink-Peters N; van der Velden J; Ten Hoor KA; Boezen HM; de Vries EG; Schilthuis MS; Mourits MJ; Nijman HW; Aalders JG; Hollema H; Pras E; Duk JM; van der Zee AG
    J Clin Oncol; 2005 Mar; 23(7):1455-62. PubMed ID: 15735121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET.
    Olsen JR; Dehdashti F; Siegel BA; Zighelboim I; Grigsby PW; Schwarz JK
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):772-7. PubMed ID: 20888130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of preoperative serum squamous cell carcinoma antigen (SCC-Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study.
    Guo Q; Zhu J; Wu Y; Wen H; Xia L; Wu X; Ju X
    Eur J Surg Oncol; 2020 Jan; 46(1):131-138. PubMed ID: 31481274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer.
    Chen W; Xiu S; Xie X; Guo H; Xu Y; Bai P; Xia X
    Radiat Oncol; 2022 Jan; 17(1):6. PubMed ID: 35012582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Validity of Using Human Squamous Cell Carcinoma Associated Antigen and Cytokeratin 19 Fragment Antigen 21-1 to Predict Postoperative Adjuvant Radiotherapy for Nonbulky Early-Stage Squamous Cell Carcinoma of the Cervix.
    Liu CZ; Zeng HX; Zhao JJ; Rong Y; Mo ZL; Li LA; Zhang JQ
    Int J Gynecol Cancer; 2017 Jun; 27(5):994-1000. PubMed ID: 28498239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance and implication on changes of serum squamous cell carcinoma antigen in the diagnosis of recurrence squamous cell carcinoma of cervix].
    Li Q; Liu S; Liu H; Zhang J; Guo S; Wang L
    Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):131-6. PubMed ID: 25877611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of serum squamous cell carcinoma antigen in patients with early cervical squamous cell carcinoma].
    Li D; Xu XX; Yan DD; Yuan SH; Lou HM
    Zhonghua Zhong Liu Za Zhi; 2019 May; 41(5):357-362. PubMed ID: 31137169
    [No Abstract]   [Full Text] [Related]  

  • 12. Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.
    Benito V; Lubrano A; Pérez-Regadera JF; Torné A; Gil-Moreno A; Tejerizo-Garcia Á; Vergés R; Díaz-Feijoo B;
    Gynecol Oncol; 2021 Aug; 162(2):407-412. PubMed ID: 34119366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence.
    Salvatici M; Achilarre MT; Sandri MT; Boveri S; Vanna Z; Landoni F
    Gynecol Oncol; 2016 Jul; 142(1):115-119. PubMed ID: 27117922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy.
    Wang W; Liu X; Hou X; Lian X; Liu Z; Shen J; Sun S; Yan J; Miao Z; Wang D; Meng Q; Fu J; Zhang F; Qiu J; Hu K
    Gynecol Oncol; 2019 Nov; 155(2):224-228. PubMed ID: 31500891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation Between Squamous Cell Carcinoma Antigen Level and the Clinicopathological Features of Early-Stage Cervical Squamous Cell Carcinoma and the Predictive Value of Squamous Cell Carcinoma Antigen Combined With Computed Tomography Scan for Lymph Node Metastasis.
    Xu D; Wang D; Wang S; Tian Y; Long Z; Ren X
    Int J Gynecol Cancer; 2017 Nov; 27(9):1935-1942. PubMed ID: 28914639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY; Huang YJ; Chanchien CC; Lin H; Wang CJ; Sun LM; Tseng CW; Tsai CC; Ou YC; Fu HC; Chen HC; Hsu HC; Wang CY
    Radiat Oncol; 2012 Jan; 7():13. PubMed ID: 22289572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Squamous Cell Carcinoma Antigen (SCC-Ag) as a Predictive Factor for the Use of Consolidation Chemotherapy in Cervical Cancer Patients After Postoperative Extended-Field Concurrent Chemoradiotherapy.
    Zhang G; Miao L; Wu H; Zhang Y; Fu C
    Technol Cancer Res Treat; 2021; 20():15330338211044626. PubMed ID: 34605696
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical significance of serum squamous cell carcinoma antigen in the diagnosis, treatment and prognosis of cervical squamous cell carcinoma].
    Luan XM; Zhang Y; Wang SZ; Wang N; Li W; Zhang Q; Wei H; Zhang SL
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(19):1330-3. PubMed ID: 22883121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive value of serum squamous cell carcinoma antigen in patients with cervical cancer who receive neoadjuvant chemotherapy followed by radical surgery: a single-institute study.
    Li X; Zhou J; Huang K; Tang F; Zhou H; Wang S; Jia Y; Sun H; Ma D; Li S
    PLoS One; 2015; 10(4):e0122361. PubMed ID: 25860888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer.
    Esajas MD; Duk JM; de Bruijn HW; Aalders JG; Willemse PH; Sluiter W; Pras B; ten Hoor K; Hollema H; van der Zee AG
    J Clin Oncol; 2001 Oct; 19(19):3960-6. PubMed ID: 11579117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.